Frazier Management’s Epizyme, Inc EPZM Stock Holding History

Frazier Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-739,369	Closed	-$1.85M	–	42
2021 Q4	$1.85M	Hold	739,369	–	–	0.14%	41
2021 Q3	$3.79M	Hold	739,369	–	–	0.3%	34
2021 Q2	$6.14M	Hold	739,369	–	–	0.57%	24
2021 Q1	$6.44M	Buy	739,369 +7,933	+1%	+$82.1K	0.52%	27
2020 Q4	$7.94M	Buy	+731,436	New	+$9.02M	0.61%	25

Other funds holding EPZM

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Frazier Management's EPZM Position: Q1 2022 in Review

Frazier Management sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 739,369 shares — an estimated $1.85M sold.

Frazier Management first reported a position in EPZM in Q4 2020 and held it in 5 quarters. The position peaked at $7.94M in Q4 2020. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

Frazier Management reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 739,369 Epizyme, Inc shares in Q1 2022, an estimated $1.85M.
Frazier Management first reported a position in Epizyme, Inc in Q4 2020 and held it in 5 quarters.
Frazier Management's Epizyme, Inc position peaked at $7.94M in Q4 2020.
120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.